New Data Supporting the Potential Use of Oxbryta® (voxelotor) in Children Ages 4 to 11 Years with Sickle Cell Disease Presented at European Hematology Association 2021 Virtual Congress

These data, along with results from two real-world evidence studies of Oxbryta, will be presented at the European Hematology Association (EHA) 2021 Virtual Congress , taking place online June 9-17, 2021.